関節リウマチにおける血清ＭＭＰ－３測定の有用性

DOI 被引用文献2件 参考文献48件
  • 大内 栄子
    第一ファインケミカル株式会社開発戦略部
  • 岩田 和士
    第一ファインケミカル株式会社開発戦略部
  • 山中 寿
    東京女子医科大学附属膠原病リウマチ痛風センター

書誌事項

タイトル別名
  • Serum MMP-3 in rheumatoid arthritis

この論文をさがす

説明

Rheumatoid arthritis (RA) is a disease raised by synovial proliferation. Overgrown synovium leads to secrete inflammatory cytokines and various kinds of proteinases. Chondrocyte and synovicyte activated by inflammatory cytokines produce extracellular matrix metalloproteinases (MMPs). Among MMPs, matrix metalloproteinase-3 (MMP-3; stromelysin-1) is considered to be the most important proteinases since MMP-3 localizes in erosive cartilage and it has a wide range of substrate specificity. Recently a one-step sandwich enzyme immunoassay (EIA) system for MMP-3 was developed and then several other assay kits have been also used clinically. A lot of clinical data of serum MMP-3 levels measured by these EIA kits have been reported. We review these clinical data of MMP-3 in various diseases and consider that the serum MMP-3 value could be a useful marker for grasping pathology of bone damage and diagnosis for RA. Serum MMP-3 levels in RA patients have been reported to be higher than healthy controls. From these clinical data, MMP-3 may reflect joint destruction and it would be valuable to predict bone damage progression, especially in the early stage of RA. The anti-cytokine therapy such as anti-TNF-α antibody and TNF-α receptor down-regulates serum MMP-3 levels in RA patient. This may suggest that MMP-3 is a useful marker for follow-up of anti-cytokine therapy. Two EIA systems for serum MMP-3, namely, PANACLEAR MMP-3[Plate] and MMP-3[BS], have been approved in Japan as diagnostic tool for RA. The value determined by each kit is different, but correlates each other. To compare with both clinical data, we recommend to convert them with the regression coefficient and to use MMP-3 value for clinical practice.

収録刊行物

  • 炎症・再生

    炎症・再生 24 (3), 154-160, 2004

    一般社団法人 日本炎症・再生医学会

被引用文献 (2)*注記

もっと見る

参考文献 (48)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ